Introduction {#s1}
============

Ever since cisplatin, the first generation of platinum antitumor agents, was approved by the U.S. Food and Drug Administration for the treatment of testicular cancer, the development of platinum antitumor agents has explosively grown during the last forty years. The second-generation product carboplatin and the third-generation product oxaliplatin were approved worldwide in succession with enlarged spectrum or decreased toxicity ([@B204]). Till today, cisplatin, carboplatin, and oxaliplatin are still extensively applied in the treatment of cancer.

Cisplatin ([**Figure 1**](#f1){ref-type="fig"}) is a neutral, square planar coordination complex of platinum(II) coordinated to two chloride and two ammonia groups, where the chloride ligands are in the cis-geometry ([@B93]). Once inside the cell, cisplatin undergoes aquation to form \[Pt(NH~3~)~2~Cl(OH~2~)\]^+^ and \[Pt(NH~3~)~2~(OH~2~)~2~\]^2+^, therefore, it becomes more reactive to DNA ([@B87]). It is approved for the treatment of advanced pancreatic cancer, breast cancer, non-small cell lung cancer (NSCLC), advanced bladder cancer et al. In the second-generation products, two chloride atoms are replaced by an oxygenated bidendate cyclobutane-dicarboxylate group to form carboplatin (cis-diammine-1,1′-cyclobutane dicarboxylate platinum II, [**Figure 1**](#f1){ref-type="fig"}), which is easier to administrate and less toxic compared with cisplatin ([@B134]). However, carboplatin has a similar anticancer spectrum with cisplatin, and the cross-resistance with cisplatin is observed in many cancer types. Oxaliplatin ({\[oxalate(2-)-O, O′\]\[1R,2R-cyclohexanediamine-N, N'\] platinum-(II)}, [**Figure 1**](#f1){ref-type="fig"}) belongs to the third generation of platinum-based antitumor agents, in which 1, 2-diaminocyclohexane (DACH) ligand substitutes for the amine groups of cisplatin. It was reported that oxaliplatin could produce fewer DNA adducts but caused higher cytotoxicity than cisplatin ([@B206]), and it also shows stronger activity in colorectal and other gastrointestinal cancers, while cisplatin and carboplatin show no efficacy. Nedaplatin (cis-diammine (glycolato-O¹, O²)platinum, [**Figure 1**](#f1){ref-type="fig"}), the second-generation platinum analogue, was first approved in Japan. It has approximately ten times as soluble in water as cisplatin and lower toxicity than cisplatin ([@B105]; [@B238]). Nedaplatin shows promising results in combination therapies ([@B115]; [@B154]; [@B186]). Lobaplatin (cis-\[trans-1,2-cyclobutanebis(methylamine)\]\[(S)-lactato-O^1^, O^2^\]platinum(II), [**Figure 1**](#f1){ref-type="fig"}), the third-generation platinum analogue, was approved in China for treatment of breast cancer, NSCLC, and chronic myelocytic leukemia ([@B204]).

![Chemical structures of platinum complexes. 1: Cisplatin; 2: Carboplatin; 3: Oxaliplatin; 4: Nedaplatin; 5: Lobaplatin.](fphar-11-00343-g001){#f1}

It's common to see patients who respond well to platinum treatment become resistant to platinum-based chemotherapy in a short time. The resistance result from (i) reduced cellular drug accumulation, (ii) increased detoxification system, (iii) increased DNA repair process, (iv) decreased apoptosis, and (v) autophagy as summarized in [**Figure 2**](#f2){ref-type="fig"}. This work reviews the updated platinum-resistance mechanisms and the key participators.

![A schematic of the mechanisms affecting platinum response. The response toward platinum-based antitumor agents can result from **(a)** cellular drug accumulation. Besides passive diffusion, the uptake of platinum agents is mediated by multiple transporters. Organic cation transporters (OCT1-3) and CTR1 mediated the influx, while ATP7A/7B and MRP2 participate in the isolation and efflux of platinum agents or GS-platinum complex. **(b)** Detoxification system. Platinum agents can be deactivated by binding to detoxification components, glutathione (GSH) and metallothionein (MT). **(c)** DNA repair process. The platinum atom can covalently bound to the N7 positions of purine bases to form the platinum-DNA adducts and induce cytotoxicity, but the DNA repair process could repair the damaged DNA lesion. **(d)** Apoptosis. Once the DNA repair fails or is overwhelmed by too many DNA lesions, apoptosis will be triggered. Mitochondria will generate excessed reactive oxygen species (ROS) to kill the cells, which might be neutralized by GSH and MT. p53 and tumor microenvironment \[including hypoxia-induced hypoxia-inducible factor (HIF) and cancer-associated fibroblasts (CAFs)\] play key regulatory roles in apoptosis. **(e)** Autophagy, a self-digestion process, has two sides in affecting platinum response.](fphar-11-00343-g002){#f2}

Transporters Involved in Platinum Influx/Efflux {#s2}
===============================================

The accumulation of platinum antitumor agents inside the cells is the necessary assurance of cytotoxicity, so decreased influx or increased efflux is responsible for platinum resistance. For many years it has been assumed that platinum enters cells by passive diffusion and through gated channels ([@B63]). However, the role of active transport mediated by multiple transporters become prominent to platinum-uptake. Three urgent questions need explanations: (i) which transporters are responsible for platinum-uptake, (ii) how transporters change during drug-resistance development, and (iii) what can be done to reverse resistance by targeting transporters.

Solute Carrier Superfamily of Membrane Transporters {#s2_1}
---------------------------------------------------

The solute carrier superfamily (SLCs) contains more than 300 members and 65 subfamilies ([@B155]) such as the organic anion transporting polypeptides, organic anion transporters, and organic cation transporters (OCTs). Normally SLCs are expressed in the whole body to sustain the cellular homeostasis by mediating the transportation of endogenous substances and exogenous substances. However, the expression or the distribution of SLCs may change under the disease condition or due to the drug--drug interaction effect, and it will have a significant effect on the cellular uptake of therapeutic drugs then leads to the unsatisfied results ([@B241]).

Cisplatin is a substrate of hOCT1 (*SLC22A1*), hOCT2 (*SLC22A2*), and hMATE1 (*SLC47A1*), and oxaliplatin is a substrate of hOCT2, hOCT3 (*SLC22A3*), hMATE1 (*SLC47A1*), and hMATE2-K (*SLC47A2*). Carboplatin and Nedaplatin are not transported by the transporters mentioned above ([@B222]). However, some contradictory results were reported probably because of the different selection of verification models, as summarized in [**Table 1**](#T1){ref-type="table"}. The down-regulation, mislocation, or inhibited transport activity of OCTs can all reduce the intracellular platinum concentration. Gao et al. reported that omeprazole could decrease the protein level of OCT2, thus lead to reduced cellular accumulation of cisplatin ([@B62]). [@B27] employed a novel fluorescent oxaliplatin derivative to discovered that OCT1 involves in oxaliplatin uptake in the sensitive but not in the resistant cell line, which may be a consequence of the altered localization of the transporter in resistant cells rather than the lower expression. Recent studies reported two crucial regulatory mechanisms of OCTs: phosphotyrosine-mediated activity regulation and epigenetic regulation. Sprowl and colleagues revealed that the phosphorylation status of Y362, mediated by the Src family kinase Yes1, might be essential for OCT2 function; hence tyrosine kinase inhibitor like dasatinib can inhibit oxaliplatin uptake and mitigate oxaliplatin-induced acute sensory neuropathy ([@B176]). Our previous work revealed the link between the epigenetic changes of OCT2 and oxaliplatin resistance in renal cell carcinoma (RCC) ([@B119]; [@B245]). We found that hypermethylated CpG islands of OCT2 disrupted the interaction between MYC and the E-Box motif, further it would prevent MYC recruiting MLL1 to catalyze H3K4me3 at the OCT2 promoter. As a consequence, the transcriptional repression of OCT2 diminished oxaliplatin accumulation and failed the oxaliplatin treatment in RCC. But decitabine, a demethylating reagent, can efficiently reverse the hypermethylation of OCT2. Therefore, the combination therapy of decitabine and oxaliplatin is a promising treatment option to reactivate RCC to oxaliplatin. The results indicated that OCT2 demethylation cracks open oxaliplatin resistance in RCC ([@B1]) and it highlights the huge potentiality of targeting transporters in clinical application.

###### 

The influx/efflux transporters of cisplatin, carboplatin, oxaliplatin, nedaplatin, and lobaplatin.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                Solute carrier superfamily of membrane transporters   ATPases   ATP-binding\   References                                                                 
                                                                                cassette\                                                                                 
                                                                                transporters                                                                              
  ------------- ----------------------------------------------------- --------- -------------- ------------ -------- ------ ------ -------- -------- ------ ------ ------ --------------------------------------------------------------------------------------------------
                OCT1                                                  OCT2      OCT3           MATE1        MATE2K   CTR1   CTR2   ATP 7A   ATP 7B   MRP1   MRP2   MRP4   ([@B77]; [@B222]); ([@B188]; [@B22]; [@B164]; [@B221]; [@B162]; [@B18]; [@B16]; [@B26]; [@B139])

  Cisplatin     ±                                                     ₊         −              ₊            −        ₊      \*     \+       \+       −      \+     \+     

  Oxaliplatin   ±                                                     \+        \+             \+           \+       \+     \*     \+       \+       \+     \+     \+     

  Carboplatin   −                                                     −         −              −            −        \+     \*     \+       \+       /      /      /      

  Nedaplatin    −                                                     −         −              −            −        /      /      /        /        /      /      /      

  Lobaplatin    /                                                     /         /              /            /        /      /      /        /        /      /      /      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

+, substrate; −, not the substrate; ±, contradictory results; \*, influenced accumulation but not proven transported substrates; /, not documented.

Copper Transporter 1/2 {#s2_2}
----------------------

Copper transporter 1 (CTR1) ubiquitously expresses in tissues and is required for high-affinity copper uptake. It is widely acknowledging that CTR1 transports cisplatin, oxaliplatin, and carboplatin ([@B77]). Deletion of the yeast CTR1 gene reduces the intracellular accumulation of cisplatin and leads to cisplatin-resistance ([@B83]), while forced overexpression of hCTR1 sensitizes small cell lung cancer cells to cisplatin, carboplatin, and oxaliplatin ([@B171]). Therefore, hCTR1 has the potentiality to become a hopeful biomarker for platinum-based chemotherapy. It can be down-regulated by intracellular copper ([@B78]) or cisplatin/oxaliplatin treatment which triggers a rapid loss of hCTR1 *via* macropinocytosis and proteasomal degradation in ovarian carcinoma cells ([@B76]) and hepatocellular carcinoma cells ([@B111]). Ishida et al. shown that copper chelator tetrathiomolybdate could increase the uptake of cisplatin into tumor cells specifically ([@B84]), and so did Fu and coworkers. They reported a combined therapy of carboplatin and trientine, a copper-lowering agent, partly reversed resistance to platinum therapy on five patients with platinum-resistant high-grade epithelial ovarian cancer ([@B55]). The proteasome inhibitors bortezomib ([@B7]) and natural compound β-elemene were also discovered that could block CTR1 from degradation ([@B111]). However, a lot of conflicting conclusions of whether regulating CTR1 levels affects sensitivity to platinum-based drugs have emerged. Kristin et al. ([@B21]) knocked out the CTR1, CTR2, ATOX1, and CCS using CRISPR-Cas9 genome editing; and the results indicated that the loss of CTR1, CTR2, ATOX1, or CCS had little impact on cisplatin sensitivity in both human HEK-293T and ovarian carcinoma OVCAR8 cells. Another research found that overexpression of CTR1 ([@B5]) failed to increase platinum accumulation and had no effect on the sensitivity of cisplatin in DLD-1 cells. The clinical relevance of hCTR1 and platinum-based chemotherapy has been questioned as well ([@B96]).

CTR2 is a low-affinity transporter of copper that shares 41% amino acid homology and the similar essential domains for copper transport with CTR1 except for the extended N-terminal domain ([@B70]). It locates at late endosomes and lysosomes, although it had also been found on the plasma membrane ([@B192]). The mRNA and protein levels of hCTR2 have significant correlations with the sensitivity of cisplatin ([@B18]). Knocking down CTR2 in some cells increases the cellular accumulation of cisplatin, yet overexpressing the CTR2 reduces the sensitivity to cisplatin ([@B79]). Blair et al. indicated that CTR2 regulated the accumulation of cisplatin through an effect on macropinocytosis, not by changing drug efflux or microsomal storage ([@B19]). Moreover, CTR2 can interact with CTR1 *via* stimulating CTR1 ectodomain cleavage resulting in less accumulation of cisplatin in cells ([@B143]).

ATP7A and ATP7B {#s2_3}
---------------

ATP7A/7B, which belongs to P-type ATPases, is responsible for copper homeostasis ([@B70]). After getting into the cells, platinum may bind to the CXXC motifs of ATP7A/B ([@B163]), then the complex translocates into a vesicle in an ATP-dependent manner with the association of copper chaperone Atox1 ([@B20]). ATP7A/B resides in the trans-Golgi network under normal conditions ([@B72]; [@B92]), but in platinum-resistance cells, it distributes in more peripherally located vesicles in the cytosol. The altered localization may be caused by reduced lysosomal compartment, and it contributes to platinum-sequestration ([@B92]). ATP7A acts as an insulator, keeping cisplatin away from nuclear in resistance cells. Chisholm and coworkers observed that the cellular platinum intensity is low and is excluded from the nucleus ([@B39]) when it shows high expression. ATP7B is also regarded as a contributor to platinum resistance and may serve as a prognostic factor. Patients with the lowest mRNA expression levels of ATP7B presented a significantly longer time to progression and had the optimal curative effects from oxaliplatin/5FU treatment in colorectal cancer ([@B131]). Given the above, it seems that downregulating ATP7A/B could be an effective way to overcome the resistance in tumor cells. By direct binding to 3′ untranslated region (3′ UTR) of the ATP7A/B mRNA, some microRNAs (miRNA, miR) regulates the cell response to cisplatin, carboplatin, and oxaliplatin such as miR-495, miR-139, and miR-133a ([@B172]; [@B198]; [@B211]). The copper chelator ammonium tetrathiomolybdate (\[(NH~4~)~2~MoS~4~\], TM) can also restore the sensitivity to cisplatin by inducing dimerization of the metal-binding domain of ATP7B ([@B53]).

Multidrug Resistance Protein Subfamily {#s2_4}
--------------------------------------

Multidrug resistance protein (MRP, ABCC) subfamily, which has seven subfamilies named A to G, belongs to the ATP-binding cassette transporter superfamily and functions as an ATP-dependent unidirectional efflux pump for anionic amphiphilic compounds ([@B88]; [@B217]). MRPs mediated the efflux of endogenous molecules, physiological substrate, and drugs (reviewed in [@B94]). MRP2, not MRP1 or MDR1, has long been recognized as the efflux transporter of the platinum-GSH conjugate ([@B188]; [@B22]). High-level expression of MRP2 is associated with intrinsic cisplatin resistance and clinical outcome in small cell lung carcinoma ([@B191]), ovarian cancer ([@B185]), and esophageal squamous cell carcinoma ([@B216]). MRP4 has also been identified as a platinum resistance-associated candidate. The overexpression of MRP4 is related to cisplatin resistance ([@B225]), and knocking down MRP4 instead of MRP1 increases the accumulation of oxaliplatin and cisplatin ([@B16]; [@B225]).

Detoxification System {#s3}
=====================

Glutathione {#s3_1}
-----------

Glutathione (L-γ-glutamyl-l-cysteinyl-glycine, GSH) plays a vital role in the cellular redox state *via* scavenging free radicals, defending cells against xenobiotics and maintaining the sulfhydryl groups of many proteins ([@B23]). The active SH-group of GSH has a high affinity to platinum, thus makes GSH become an easy, non-DNA-related target ([@B246]). The GS-platinum complex catalyzed by glutathione-S-transferase can reach to about 60% of the intracellular platinum content after 12-h incubation in leukemia cells ([@B85]), and the elevated expression of GSH and glutathione-S-transferase are often seen in the resistant-cells ([@B133]; [@B28]). Preventing the formation of the GS-platinum complex may reverse the platinum resistance efficiently. One choice is to use competitive inhibitors of GSH such as \[Cu(phen)(H~2~O)~2~(ClO~4~)~2~\] (C10) ([@B29]), another is to interfere with the synthesis of GSH. Two enzymes mediate the production of GSH, γ-glutamylcysteine ligase and GSH synthetase. In the first step, γ-glutamylcysteine ligase catalyze glutamate and cysteine to form γ-glutamylcysteine; then, in the second step, GSH synthetase catalyzes γ-glutamylcysteine and glycine to form GSH ([@B9]). GSH-depleting agents buthionine sulfoximine is a useful agent for inhibition of γ-glutamylcysteine ligase, and it reduced the resistance to cisplatin in malignant glioma ([@B159]). However, non-specific GSH depletion can cause irreversible damage in most normal tissues. Hence selective tumor GSH depletion appears to be a better choice but remains as a superb challenge (reviewed in [@B50]). Cystine is normally used as the precursor for GSH synthesis due to the chemical instability of cysteine, and the intracellular cysteine/cystine level is maintained by the xc^−^ system which mediates the uptake of cystine; so finding ways to inhibit xc^−^ system can block the synthesis of GSH. Sulfasalazine ([@B126]) and salubrinal ([@B199]) are both reported as powerful blockers. Epigenetic interference also involves in the regulation of the GSH synthesis: miRNA-27a negatively regulates the xc^-^ ([@B48]); G9a, a transcriptional corepressor that catalyzes histone 3 lysine 9 dimethylation, transcriptional activates the glutamate-cysteine ligase catalytic subunit, and lead to the elevation of GSH level in head and neck squamous cell carcinoma ([@B120]); Linc RNA (Lnc RNA, Lnc) H19 participates in the production and regeneration of GSH in high-grade serous ovarian cancer ([@B235]).

GSH redox cycle also regulates platinum resistance. GSH can be oxidized into GSSG by GSH peroxidase using H~2~O~2~ as a substrate, whereas GSSG can be reduced back to GSH by GSSG reductase using NADPH as a cofactor ([@B33]). Higher expression of glutathione reductase accompanied by lower levels of endogenous reactive oxygen species (ROS) contributes to the cisplatin-resistance ([@B244]).

Metallothionein {#s3_2}
---------------

Platinum antitumor drugs are also inactivated by chelating with metallothionein (MT) proteins. MTs are low-molecular-weight metal-binding proteins containing one-third cysteine residues, which make MTs become easy targets for platinum to chelate ([@B99]). Platinum agents may also bind to metal transcription inhibitor and release the metal transcription factor-1 to trigger the biosynthesis of MTs ([@B101]). It has been found that MTs level is increased not only in the tumor tissue but also in the serum of cancer patients ([@B190]); RNA interference can inhibit the overexpression of MTs efficiently and reverse platinum resistance ([@B106]). Expressing level of the MTs has been considered as an important biological factor of platinum-based chemotherapy ([@B215]), but rather than global MTs classes, Habel and colleagues suggested that MT isoforms are more valuable prognosis predictors markers ([@B71]). Pekarik et al. noted that MT-1 and MT-2 have redundant binding sites for many miRNAs, including miR23 and miR224 ([@B153]). It indicated that miRNAs may involve in the regulation of MTs, and could be a notable pointcut.

DNA Repair {#s4}
==========

The platinum atom can covalently bound to the N7 positions of purine bases to form the platinum--DNA adducts. Cisplatin can form mono adducts, intrastrand, or interstrand cross-links, but the 1,2-intrastrand crosslinks account for over 90% (reviewed in [@B87]; [@B30]). It is well acknowledged that forming DNA adducts is the determinant step for cytotoxicity of platinum-based antitumor agents because the platinum--DNA complexes influence the structure of DNA double helix ([@B93]) and nucleosomes ([@B45]). As a result, it causes replication and transcription inhibition and DNA double-strand breaks (DSBs), followed by the initiation of DNA repair. Once the DNA repair fails or is overwhelmed by too many DNA lesions, cell death will be triggered (reviewed in [@B91]). The increased DNA repair process is considered as the most significant characteristic in platinum-resistance cells ([@B47]; [@B208]), with the exception of DNA mismatch repair whose deficiency gives rise to cisplatin/carboplatin resistance ([@B165]), but has less influence to oxaliplatin ([@B67]). Oxaliplatin has more potent cytotoxicity than cisplatin for inducing early secondary DSBs and massive apoptosis ([@B51]). However, Bruno et al. reported that oxaliplatin induces ribosome biogenesis stress rather than DNA damage to kill cells ([@B25]). Most intrastrand crosslinks are removed by nucleotide excision repair (NER) system *via* excising damaged nucleotides and synthesizing DNA to reconstitute genetic integrity, while other lesions are repaired by complex-combined mechanisms ([@B161]). Only two key components of the DNA repair system will be discussed in this review.

Excision Repair Cross-Complementing {#s4_1}
-----------------------------------

All excision repair cross-complementing (ERCC) members have their unique roles in DNA repair progress, and their expression level or SNP has a significant impact on platinum resistance. In a prospective study, Sullivan et al. analyzed the SNPs in eight DNA-repair related genes and found that after the treatment of platinum-based chemotherapy, the response of patients with stages III significantly associated with SNPs in ERCC1 and ERCC3 genes, while the response of patients with stage IV associated with a genetic variant in the ERCC4 gene ([@B180]). Many researchers highlight the relevance between ERCC1 and platinum-treatment response ([@B108]; [@B146]). Liu et al. found that under DNA damage condition, p53 recruited CITED2/P300 along with chromatin relaxation H3K9Ac or H3K14Ac to bind with the ERCC1 promotor, and activated the DNA repair process ([@B118]). However, Spada et al. reported that ERCC1 had no significant correlation with the clinical outcome with oxaliplatin-based chemotherapy in advanced neuroendocrine tumors ([@B175]). ERCC4 (XPF), a necessary component in NER, interstrand cross-links repair, homologous recombination repair (HRR) but not in non-homologous end-joining ([@B107]), contributes to the intrinsic resistance of cisplatin, and its expression level is tissue-specific ([@B227]). ERCC1 and XPF can form the human ERCC1--XPF complex which works as a nuclease in NER and the late stage of HRR ([@B64]; [@B8]). Arora et al. reported that knocking down ERCC1--XPF resulted in reduced intrastrand repair and interstrand crosslinks repair, which makes about fourfold to sixfold changes in IC~50~ value of cisplatin in NSCLC cells ([@B10]). Based on the above results, it is reasonable to believe that inhibiting ERCC1/XPF is a potential way to sensitize tumor cells to platinum-based chemotherapy, and many inhibitors are discovered: green tea polyphenol epigallocatechin-3-gallate, catechols, 3-hydroxypyridones, N-hydroxyimides, and hydroxypyrimidones ([@B32]; [@B195]), but their clinical application still needs further investigation. Another nuclease function as ERCC1--XPF in NER is ERCC5 (XPG), which also relates to platinum sensitivity. Graf et al. reported that XPF and XPG knockdown increased the platinum-induced cytotoxicity in osteosarcoma cells ([@B68]). Interestingly, platinum-based chemotherapy is influenced by the 5′ noncoding mRNA element of ERCC5. Somers's group discovered a common polymorphic variant rs751402 in the ERCC5 5′ untranslated region, which generated an upstream ORF, and the carriers with early childhood ependymoma were markedly resistant to platinum-based agents ([@B170]).

Breast Cancer Susceptibility Gene {#s4_2}
---------------------------------

Breast Cancer Susceptibility Genes (BRCAs) involve in the repair of DSB and DNA cross-linking damage induced by DNA-damaging agents through the HR pathway (reviewed in [@B54]); BRCA1/2-deficient carcinomas have impaired HRR and become more sensitive to platinum agents ([@B46]; [@B138]). The alterations or mutations of BRCA1 and BRCA2 lead to the impaired recognition of DNA damage, and therefore depending on the patients' BRCA status to add platinum agents into neoadjuvant therapy before surgery could receive an excellent response ([@B65]; [@B174]). However, in BRCA mutant cancers, platinum resistance still exists. To explain that phenomenon, Guillemette et al. conducted a genome-wide shRNA screen and found that loss of the nucleosome remodeling factor CHD4 might cause cisplatin resistance through a trans-lesion synthesis dependent manner rather than HRR in BRCA2 mutant cancer cells([@B69]). In addition, a secondary mutation in BRCA1/2 may occur after patients receiving platinum-based chemotherapy treatment, and it restores the function of BRCA1/2, ending with platinum resistance ([@B142]). Researchers recently found two regulators: Wwox and deubiquitination enzyme USP13. Wwox can interact with BRCA1 and tip the DSBs repair pathway choice, and its deficiency permits significantly increased resistance to cisplatin, so it could be an efficient predictor of response to cisplatin ([@B166]). The knockdown of USP13 dramatically diminishes cisplatin-induced RAP80-BRCA1 foci formation, for its deficiency decreases the bind between RAP80 and K63-linked ubiquitin chain and fail the BRCA1 recruitment ([@B114]).

Other than ERCC and BRCA, many key components like FANCD2 ([@B130]), PCNA ([@B169]), XRCC1 ([@B213]), and RAD51 ([@B148]; [@B210]), also play different roles in multiple DNA repair pathway. A better understanding of the DNA repair regulation network will provide a more accurate guide to personalized platinum-based chemotherapy.

Apoptosis {#s5}
=========

After binding to the DNA, the core downstream events platinum agents triggered is apoptosis, which is also called programmed cell death. Two main apoptosis pathways have been well proposed: the extrinsic and the intrinsic pathways. The extrinsic pathway is activated after the tumor necrosis factor family binding to the cell surface receptors of the tumor necrosis factor receptor superfamily and leads to the self-activation of initiator caspase-8. The intrinsic pathway is switched by an imbalance between proapoptotic (i.e., BAX, BAK) and antiapoptotic proteins (i.e., BCL-2, BCL-XL, BCL-w). Upon activation, proapoptotic signaling leads to mitochondrial outer membrane permeabilization, and then cytochrome c will be released, initiating a series caspase cascade ([@B95]; [@B11]). Platinum-resistant tumor cells usually have a higher threshold for apoptosis induction, mostly due to the overexpression of anti-apoptotic proteins or the defect in mitochondrial signaling. Many factors contribute to these unwanted phenomenons, such as pro-survival signal pathways ([@B181]; [@B12]) \[i.e., MAPK/ERK ([@B100]), PI3K/AKT pathway, NF-κB ([@B136])\], and tumor microenvironment (TME) and epigenetic regulation ([@B15]; [@B157]). Researchers begin focusing on the critical role of non-coding RNA in diverse cellular processes; studies demonstrated that non-coding RNA broadly participated in proapoptotic/antiapoptotic proteins regulation and could work as therapeutic targets or predict markers ([@B34]; [@B224]). We summarized recently found apoptosis-related non-coding RNA with details listed in [**Table 2**](#T2){ref-type="table"}. Among all the contributors, we specifically concentrate on the role of p53 and TME in platinum resistance.

###### 

The LncRNAs and miRNAs regulate platinum resistance through targeting apoptosis and autophagy in various cancer.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                           Target                       Platinum agents                       Cancer type                    References
  ------------------- --------------------------------------- ---------------------------- ---------------------------- ------------------------------------- ------------------------------ ------------
  Apoptosis           LncRNA                                  LncRNA UCA1                  miR-184/SF1                  Cisplatin                             Oral squamous cell carcinoma   ([@B52])

  CREB-miR-196A-5P    Bladder cancer                          ([@B149])                                                                                                                      

  LncRNA AC023115.3   miR-26a-GSK3β                           Malignant glioma             ([@B127])                                                                                         

  LncRNA XIST         let-7i/BAG-1                            Lung adenocarcinoma          ([@B183])                                                                                         

  LINC00473           C/EBPβ\                                 Osteosarcoma                 ([@B229])                                                                                         
                      IL24                                                                                                                                                                   

  HOMEOBOX A11        miR‐454‐3p/Stat3                        Lung adenocarcinoma          ([@B232])                                                                                         

  HOTAIR              PI3K/Akt\                               Gastric cancer               ([@B38])                                                                                          
                      Wnt/β-catenin\                                                                                                                                                         
                      miR-34a                                                                                                                                                                

  Lnc PVT1            HIF1α                                   ([@B226])                                                                                                                      

  miRNA               miR−34a                                 MAGE-A/p53                   Carboplatin                  Retinoblastoma                        ([@B220])                      

  miR-205\            Mcl-1\                                  Lung cancer                  ([@B224])                                                                                         
  miR-218             Survivin                                                                                                                                                               

  miR-634             Ras-MAPK                                Ovarian cancer               ([@B193])                                                                                         

                                                              miR-139-5p                   MAPK                         Cisplatin                             Ovarian cancer                 ([@B37])

  miR-5100            Rab6                                    Lung cancer                  ([@B219])                                                                                         

  miR-873             Bcl-2                                   Gliomas                      ([@B34])                                                                                          

  miR-199a-3p         ZEB1                                    Melanoma                     ([@B116])                                                                                         

  miR-195             Prohibitin 1                            ([@B41])                                                                                                                       

  miR-125a-5p         STAT3                                   Esophageal carcinoma         ([@B233])                                                                                         

  miR-374a            PDCD4                                   Nasopharyngeal carcinoma     ([@B234])                                                                                         

  miR-146a            Cyclin J                                Non-small cell lung cancer   ([@B167])                                                                                         

  miR-148b            DNMT1                                   ([@B179])                                                                                                                      

  miR-200c            AKT2                                    Osteosarcoma                 ([@B123])                                                                                         

  miR-378             Clusterin                               Lung adenocarcinoma          ([@B35])                                                                                          

  miR-216b            PARP1                                   Ovarian cancer               ([@B122])                                                                                         

  miR-148a            Rab14                                   Renal cell carcinoma         ([@B97])                                                                                          

  miR-126             SERPINE1\                               ([@B121])                                                                                                                      
                      SLC7A5\                                                                                                                                                                
                      mTOR/HIF                                                                                                                                                               

  miR-17-92           AKT                                     Prostate cancer              ([@B240])                                                                                         

                                                              miR-99a\                     CAPNS1                                                             Gastric cancer                 ([@B228])
                                                              miR-491                                                                                                                        

  Autophagy           LncRNA                                  BLACAT1                      miR-17/ATG7                  Cisplatin                             Non−small cell lung cancer     ([@B81])

  MALAT1              microRNA−30b/autophagy−related gene 5   Gastric cancer               ([@B209])                                                                                         

  miRNA               miR-634                                 APIP/XIAP/BIRC5/OPA1 NRF2    Cisplatin                    Esophageal squamo-us cell carcinoma   ([@B57])                       

  miR-148A-3p         RAB12\                                  Gastric cancer               ([@B113])                                                                                         
                      mTORC1                                                                                                                                                                 

  miR-874             ATG16L1                                 ([@B80])                                                                                                                       

  miR-let-7f-1        HMGB1                                   Medulloblastoma              ([@B151])                                                                                         

  miR-181             PTEN/PI3K/AKT/mTOR                                                   Non-small cell lung cancer   ([@B124])                                                            

  miR-409-3p          Beclin-1                                Oxaliplatin                  Colon cancer                 ([@B187])                                                            

  miR-218             YEATS4                                  Colorectal cancer            ([@B56])                                                                                          

  miR-34a             TGF-β/Smad4 pathway                     ([@B182])                                                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LncRNA, long non-coding RNA; miRNA, microRNA.

p53 {#s5_1}
---

The tumor suppressor p53 functions mainly as a transcriptional activator of many cellular programs, including checkpoint activation, DNA repair, and apoptosis, and therefore the status of p53 is crucial for the cytotoxicity of platinum agents ([@B59]). Downstream genes of p53 related with apoptosis include FAS, BBC3, BAX, and BIRC5 ([@B158]). Besides the nuclear function, p53 located in cytoplasmic also promotes apoptosis through directly targeting mitochondria (reviewed in [@B129]). However, it is common to see the loss or mutation of p53 in the patients ([@B2]; [@B178]), and the disfunction of p53 will cause the failure of checkpoint response, cell cycle arrest, programmed cell death (apoptosis), and permanent cell cycle arrest (senescence) ([@B132]). Eventually, it leads to a poor outcome of platinum-based chemotherapy. A thought-provoking work reported a nonsynonymous single-nucleotide polymorphism Pro47Ser (rs1800371) in African descent; the carriers are more tumor-prone and show a significant defect in cisplatin-induced cell death due to the impaired trans-activation ability ([@B89]). For this reason, more precision medicine approaches should be considered for different mutation carriers ([@B13]).

Antirepression, stabilization, DNA binding, and transcriptional activation are four key steps in p53's activation along with an exquisite regulation network including phosphorylation, ubiquitination, methylation, sumoylation, neddylation, and acetylation (reviewed in [@B102]). Ubiquitinate-dependent degradation of p53 is mediated by human double minute 2 (HDM2, MDM2); therefore, interference with the HDM2/p53 pathway is an optional strategy to rescue p53 from degradation and reactivate it. Two p53-MDM2 blockers, RITA ([@B86]) and nutlin ([@B194]), were discovered in 2004. Furthermore, recently Wanzel and coworkers used CRISPR-Cas9 based target validation to reveal the actual mechanisms of two p53-MDM2 blockers ([@B203]). Nutlin was designed to blocks the p53-binding pocket of Mdm2 and RITA was to bind the Mdm2-interacting N terminus of p53, but on the contrary, results showed that the activity of nutlin strictly depends on functional p53 while the sensitivity of RITA correlates with induction of DNA damage but not with p53 ([@B203]). The phosphorylation status is also vital to functional p53. DACH-diacetato-dichloro-Pt(IV) (DAP) and oxaliplatin circumvent cisplatin resistance for phosphorylating p53 at Ser20 in resistant cells while cisplatin cannot ([@B212]), and in cisplatin-resistant MCF-7 cells, resveratrol induces serine 20 phosphorylation to activate p53 target genes such as PUMA and BAX, restoring apoptosis ([@B74]). All these results demonstrate that phosphorylation at Ser 20 site might be a critical event for p53 activation.

TME {#s5_2}
---

The TME is a complex ecosystem and an active regulator in the progression of cancer development. The interaction between TME and cancer cells is mutual and dynamical. Tumor epithelial cells can gradually change the nature of the microenvironment, such as hypoxia, and conversely, the altered TME will regulate tumor development ([@B14]). TME consists of nonmalignant cells of the tumor such as cancer-associated fibroblasts (CAFs), endothelial cells and pericytes composing tumor vasculature, immune and inflammatory cells, bone marrow-derived cells, and the extracellular matrix ([@B14]). Some have been proven participating in the formation of drug resistance.

### CAFs {#s5_2_1}

The CAFs, which held the main proportion of tumor stroma, are perpetually activated, and neither revert to a normal phenotype nor undergoes apoptosis and elimination ([@B109]). Emerging evidence demonstrates that non-malignant CAFs can contribute to tumor proliferation, metastasis, and chemoresistance. CAFs secrete specific cytokines, proteins, or exosomal miRNA to activate certain anti-apoptosis related signaling pathways like PI3K/Akt, ANXA3/JNK, and IL-11/IL-11R/STAT3, and consequently offer tumor cells the ability of resistance ([@B189]; [@B239]; [@B237]; [@B156]; [@B201]). CAFs can also cause the aberrant remodeling of extracellular material and physical properties of the tumor altered, or release cysteine and GSH to limit the intracellular platinum concentration ([@B6]; [@B197]). It is worth mention that most of these researches focus on the resistance change of tumor cells after platinum treatment. However, the innate chemoresistant of CAFs is poorly understood. Qin X et al. recently reported that HNC-derived CAFs were innately resistant to cisplatin, maybe due to the high expression of ERCC1 and ERCC4 ([@B156]).

### Hypoxia {#s5_2_2}

The imbalance between the rapid growth of tumor cells and inadequate supply from blood vessels alters the TME, and one of the significant characteristics is hypoxia ([@B17]), which is strongly associated with a poor prognosis in different cancer types, such as hepatocellular carcinoma ([@B43]), ovarian cancer ([@B145]), NSCLC ([@B82]), etc. Hypoxia triggers the regulation of hypoxia-inducible factor (HIF) family at the transcription level and protein level ([@B152]). HIFs are heterodimeric transcription factors composed of two parts: an oxygen-labile alpha subunit (HIF1α, HIF2α, or HIF3α) and a stable beta subunit (HIF1β). HIF1α and HIF2α are widely expressed in various tissues and have been well understood, yet HIF3α is less known due to its high specificity of tissue distribution and the existence of multiple variants ([@B49]). So only HIF1α and HIF2α will be discussed in this review. Under normoxic conditions, two specific proline residues in HIF-1α are hydroxylated by HIF prolyl hydroxylase enzymes with the cofactor oxygen, iron, ascorbate, and 2-oxoglutarate. Then, the hydroxylated HIF1α protein is bound with the von Hippel--Lindau protein, and it will recruit E3 ubiquitin ligases and put HIF1α through polyubiquitination and degradation by the 26S proteasome. Whereas under hypoxic conditions, impaired hydroxylation process stabilizes the HIF1α protein, furthermore HIF1α will translocate into nuclear and dimerize with HIF1β to transactivate the target genes which relate with glucose metabolism, angiogenesis, cell proliferation, invasion and metastasis (reviewed in [@B152]; [@B173]). HIF1α has a strong association with apoptosis; it regulates apoptosis-related genes (i.e., Bcl-2, Bax, caspase 3, caspase 8) ([@B73]; [@B231]), and survival signaling pathways such as NF-κB ([@B160]). Zheng et al. recently found that HIF-1α could activate the PI3K/AKT by up-regulating Mxd1 expression to suppress the PTEN expression ([@B236]). Besides, HIF accumulation facilitates the secretion of several growth factors and further activates mTOR to form a positive feedback circuit. Deactivating these signaling pathways *via* reducing HIFs could be a promising approach.

Highly proliferative cancer cells switch glucose flux from oxidative phosphorylation to anaerobic glycolysis, which converts pyruvate into lactate even in the presence of oxygen (the Warburg effect). This shift will quench cytosolic ROS ([@B75]). However, recent evidence shows that in some cytotoxic antineoplastic drug-resistance tumor cells, aerobic glycolysis can shift back to oxidative phosphorylation ([@B214]). HIFs act as inducers to aerobic glycolysis and a suppressor to mitochondrial function; it can regulate many main enzymes in glycolysis and tricarboxylic acid cycle like GLUT1, LDH-A, PDH, and PDK1 ([@B140]). Downregulating HIF-1α to redirect the aerobic glycolysis towards oxidative phosphorylation resulting in overexpressing ROS can resensitize the cisplatin-resistance ovarian cancer cells ([@B4]). ROS act as a double-bladed sword in the platinum treatment. On the one hand, platinum agents-induced cytotoxicity is strongly linked to excessed ROS generation ([@B24]; [@B40]; [@B90]; [@B112]). Unlike cisplatin, oxaliplatin prefers to stimulate O~2~^--^ production rather than H~2~O~2~ ([@B36]). Some essential components were newly discovered. Wang et al. reported that Scribble promotes cisplatin-induced apoptosis *via* protecting Nox2/ROS ([@B200]). Inositol 1, 3, 4, 5-tetrakisphosphate, the product of inositol-trisphosphate 3-kinase B, inhibits NADPH oxidase 4, thereby inhibiting the generation of cisplatin-induced ROS ([@B150]). The imbalance between ROS production and elimination is often seen in resistance cells. Besides GSH and MTs, the elevated oxidative branch of the pentose phosphate pathway is another strong defensor against ROS ([@B214]). The key, it seems, is whether the ROS level can reach the threshold to trigger cell death. Stimulating the production or blocking the neutralization of ROS might be a promising way to reverse platinum resistance. On the other hand, the increased ROS level in cancer cells might accelerates the development of tumor aggressiveness and drug resistance ([@B103]). Increased ROS can activate cellular survival pathways including c-Myc--miR-137--EZH2 pathway ([@B184]), IL-11--JAK2--STAT5 pathway ([@B242]), ATR--Chk1 pathway ([@B135]) and AXL ([@B144]) et al. ROS may also mediate metabolism reprogramming ([@B42]).

Classical strategies include direct/indirect HIF targeting and interference in upstream/downstream HIF regulators/signaling pathways. Many prodrugs, specific HIF inhibitors, and non-selective inhibitors are developed to inhibit HIFs with many different mechanisms including inhibition of HIF dimerization, mRNA or protein expression, transcriptional activity, and DNA binding capacity (reviewed in [@B205]). Recently found Trx-1 and KLF5 ([@B110]) are upstream regulators of HIF 1α. Trx-1 increase the expression and the binding capacity of HIF1α through enhanced interaction with Ref-1 and inhibition of Trx-1/Ref-1 axis can strengthen the oxidative phosphorylation, and reverse the resistance to cisplatin ([@B230]). Gong et al. reported KLF5 knockdown suppressed hypoxia-induced cisplatin resistance by inhibiting HIF1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway ([@B66]). Non-coding RNAs can also increase the expression of HIF1α, resulting in platinum resistance ([@B226]; [@B121]).

Besides HIF1α, HIF2α also associate with platinum response. GBM cells show an increase in cisplatin resistance after exposure to hypoxia, and downregulating HIF2α, not HIF1α, significantly sensitizes U251 and U87 cells (GBM cell lines) to cisplatin ([@B3]). Knocking down HIF2a significantly increases the sensitivity to cisplatin in A549 cells ([@B61]).

Autophagy {#s6}
=========

Autophagy, a "self-digestion" process, occurs in all eukaryotes. It is essential for nutrient regulation and intracellular quality control and homeostasis ([@B137]). Also, autophagy functions as a self-defense strategy by recycling macromolecules as an alternative energy source. However, if autophagy continuously or excessively proceeds, cell death will be triggered. There are generally three major types of autophagy, macroautophagy, microautophagy, and chaperone-mediated autophagy. In this review, only macroautophagy (referred to as autophagy) will be discussed. Macroautophagy seems to have a conflicting role in tumorigenesis and progression. It can act as a prodeath or prosurvival role at different cancer stages (reviewed in [@B44]). After platinum treatment, the increased drug-induced autophagy is observed in platinum-resistant cells, along with the increased basal autophagy ([@B223]; [@B117]; [@B207]; [@B60]; [@B202]). Inhibition of autophagy *via* autophagy inhibitor or interference in regulatory elements or noncoding RNAs has been proven can reduce the platinum resistance. Using 3-methyladenine or chloroquine to inhibit early/later-stage autophagy can both enhance platinum-mediated cytotoxicity ([@B58]; [@B125]). Autophagy is highly controlled by regulatory elements including PI3K--Akt--mTOR pathway, Beclin1, Bcl-2, Ras, p53, and noncoding RNAs \[long non-coding RNAs (LncRNs) and miRNAs\] (reviewed in [@B104]). Recently, new regulators dual-specificity protein phosphatase 1 (DUSP1) ([@B196]), heparinase ([@B168]), and HMGB1 ([@B117]), GFRA1 ([@B98]) are reported. Targeting these regulatory elements can restore the efficiency of platinum agents. LncRNAs and miRNAs affect the platinum resistance by targeting key components like ATG7 or signaling pathways like PI3K/AKT/mTOR in autophagy. We summarized recently found autophagy-related non-coding RNA with details listed in [**Table 2**](#T2){ref-type="table"}.

Another big issue caused by autophagy is related to cancer stem cells (CSC). CSCs are a subpopulation of cancer cells within the tumor that have the ability to self-renew and to differentiate. CSCs have long been considered as the main culprit for drug resistance and relapse ([@B128]; [@B177]). Growing evidence indicated that autophagy protects CSCs for participating in the regulation of stem cell differentiation, somatic reprogramming and self-renewal capacity ([@B147]). Yang et al. reported that oxaliplatin-induced autophagy enriches the population of colorectal CD44^+^ CSCs and maintain the stemness of colorectal CSCs, this protection eventually causes chemoresistance in colorectal CSCs ([@B218]), and so did Nail's group. They found that autophagy regulates the expression of stemness surface marker CD44, drug resistance marker ABCB1 and invasion mediator ADAM17 to help maintain stemness and chemoresistance, but the mechanism remains unclear ([@B141]). Targeting autophagy to diminish the CSCs subpopulation might be a new direction to overcome platinum resistance.

In most aforementioned cases, increased autophagy has a negative relation to platinum response. However, some phytochemicals show anti-resistance effects *via* inducing autophagy. Zhu et al. reported that hyperoside sensitizes ovarian cancer cells to cisplatin relay on PGRMC1-dependent autophagy ([@B243]); resveratrol can induce autophagy and apoptosis in cisplatin-resistant human oral cancer ([@B31]).

Further investigation about the changeful role of autophagy in tumor development and the complex regulatory mechanism involved in will provide more potential intervention targets and approaches for how and when to overcome platinum resistance.

Conclusions {#s7}
===========

The resistance of platinum agents is still an ordeal. Elucidating the molecular mechanisms underlying the resistance phenomena will largely extend the clinic application of platinum agents. The main mechanisms are summarized as changed cellular platinum accumulation, increased detoxification system, increased DNA repair, decreased apoptosis, and autophagy. As the relative technologies develop rapidly, new research means such as CRISPR-Cas9, RNAi-based functional genetic screening help researchers to reexamine some key regulators and illuminate their actual impact on platinum resistance. Another notable tendency is the deeper understanding of the epigenetic modification. Non-coding RNA shows extremely complicated regulation functions on all sides and the potential to be predictive markers. The intercrossed application among genome, epigenome, transcriptome, proteome, and metabolome systems will provide a new aspect to break through the bottlenecks. But the challenges still remain as to how to utilize the emerged candidate targets as predictive markers to assign patients to more promising therapy or as therapeutic targets to improve the curative effect of platinum-based antitumor agents.
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